Navepegritide Trial Results for Children with Achondroplasia
TransCon CNP (navepegritide) met the primary endpoint in the 52-week, randomized, double-blind ApproaCH trial, delivering a statistically significant increase...
eClinical Tech News
Protara to Present New TARA-002 Data for NMIBC Patients
Protara TherapeuticsProtara Therapeutics will present interim safety and efficacy data from 31 BCG‑naïve patients in Cohort A of the...
Acumen Launches New Phase 2 Study for Alzheimer’s Drug
Phase 1 data for sabirnetug (ACU193) showed a favorable safety profile with low overall rates of ARIA-E and evidence...
New First-in-Class Fibromyalgia Drug Tonmya Launches in US
Across two double-blind Phase 3 studies in nearly 1,000 adults with fibromyalgia (RELIEF, n=503; RESILIENT, n=457), TONMYA (cyclobenzaprine HCl...
ORIC-944 Trial: Remarkable Efficacy and Safety Results
Topline efficacy from ORIC’s Phase 1b mCRPC study shows a 55% PSA50 response rate (11/20) with 40% confirmed (8/20),...
Inspira’s New Hyla™ Blood Sensor Completes Clinical Study
Reported accuracy came in at 95% to 99% across measured parameters in Inspira Technologies’ clinical study and ongoing lab...
Cognition Finishes Enrollment for Early Alzheimer’s Study
Enrollment is complete at 540 participants in START, a randomized, placebo-controlled Phase 2 trial of zervimesine (CT1812) in mild...
Trinity Biotech to Advance Prostate Cancer Test with Partner
An earlier study reported that when combined with PSA, Trinity Biotech’s EpiCapture correctly identified all high-grade prostate cancers in...
MIMEDX Provides Update on EpiEffect® Randomized Trial
Interim results from the CAMPAIGN randomized controlled trial reported a 98.5% posterior probability that lyophilized human amnion/chorion membrane (EPIEFFECT)...
Biox-101 Data Shows Breakthrough Potential for Stroke Care
Bioxodes reported encouraging Phase 2a signals for BIOX-101 in intracerebral hemorrhage, including a reduction in hematoma among all treated...